Related Experiment Video
Updated: Jul 24, 2025

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
Published on: February 14, 2011
Monoclonal antibodies as COVID-19 prophylaxis therapy in immunocompromised patient populations
Juthaporn Cowan1, Ashley Amson2, Anna Christofides2
1Department of Medicine, Division of Infectious Diseases, University of Ottawa, The Ottawa Hospital, 501 Smyth Road, Ontario K1H 8L6 Ottawa, Canada; Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ontario K1H 8L6, Ottawa, Canada; Centre for Infection, Immunity and Inflammation, Ontario K1H 8M5 Ottawa, Canada.
Objectives:
The objective of this review was to examine the latest literature regarding the effectiveness of monoclonal antibodies as COVID-19 prophylaxis therapy for immunocompromised patient populations.
Methods:
Literature review of published real-world and randomized control trials (RCTs) from 2020 to May 2023.
Results:
COVID-19 is highly transmissible with potentially serious health outcomes, underscoring the need for effective prevention and treatment strategies. Vaccines are highly effective at preventing COVID-19 for the general population; however, efficacy is often impaired in immunocompromised patients given insufficient response to initial exposure and/or memory for secondary exposures. Some individuals may also have contraindications to vaccination. As such, additional protective measures are needed to bolster the immune response in these populations. Monoclonal antibodies have been effective at bolstering immune system responses to COVID-19 among immunocompromised patients; however, they are proving ineffective against the most recent Omicron strains (BA.4 and BA.5).
Conclusion:
Several studies have investigated the efficacy of monoclonal antibodies as pre- and post-prophylaxis for COVID-19. Historical evidence is promising; however, new variants of concern are proving challenging for currently available regimens.
More Related Videos
Related Concept Videos
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Tumor Immunotherapy
Myocarditis III: Medical Management

